Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Operating Leases (2021 - 2025)

Nurix Therapeutics (NRIX) has disclosed Operating Leases for 5 consecutive years, with $55.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 174.68% to $55.7 million in Q4 2025 year-over-year; TTM through Nov 2025 was $55.7 million, a 174.68% increase, with the full-year FY2025 number at $55.7 million, up 174.68% from a year prior.
  • Operating Leases was $55.7 million for Q4 2025 at Nurix Therapeutics, up from $52.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $55.7 million in Q4 2025 to a low of $2.6 million in Q3 2023.
  • A 5-year average of $17.4 million and a median of $10.3 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: surged 679.33% in 2024, then crashed 72.23% in 2025.
  • Nurix Therapeutics' Operating Leases stood at $9.2 million in 2021, then fell by 29.98% to $6.4 million in 2022, then surged by 259.42% to $23.1 million in 2023, then dropped by 12.26% to $20.3 million in 2024, then soared by 174.68% to $55.7 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Operating Leases are $55.7 million (Q4 2025), $52.7 million (Q3 2025), and $5.8 million (Q2 2025).